OTCMKTS:CMPD

CompuMed - CMPD Competitors

$3.00

+0.30 (+11.11%)

(As of 03/20/2023 12:00 AM ET)

Add

Compare

Today's Range: $3.00
▼
$3.29
50-Day Range: $2.68
▼
$3.49
52-Week Range: $2.60
▼
$5.00

Volume: 2,784 shs
Average Volume: 1,616 shs
Market Capitalization: $3.56 million

P/E Ratio: 9.38
Dividend Yield: N/A
Price Target: N/A

CMPD vs. KERN, MGTI, ACUR, MEDS, SLHG, HOTH, REMI, GENN, BXRX, and PTPI

Should you be buying CompuMed stock or one of its competitors? The main competitors of CompuMed include Akerna (KERN), MGT Capital Investments (MGTI), Acura Pharmaceuticals (ACUR), TRxADE HEALTH (MEDS), Skylight Health Group (SLHG), Hoth Therapeutics (HOTH), Remedent (REMI), Genesis Healthcare (GENN), Baudax Bio (BXRX), and Petros Pharmaceuticals (PTPI). These companies are all part of the "medical" sector.

CompuMed vs.

CompuMed (OTCMKTS:CMPD) and Akerna (NASDAQ:KERN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

: CompuMed has higher earnings, but lower revenue than Akerna. Akerna is trading at a lower price-to-earnings ratio than CompuMed, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CompuMed $6.36 million 0.56 $1.07 million $0.32 9.38
Akerna $20.68 million 0.15 -$31.33 million -$43.59 -0.02
: Akerna has a consensus price target of $1.75, suggesting a potential upside of 124.36%. Given Akerna's higher possible upside, analysts clearly believe Akerna is more favorable than CompuMed.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CompuMed
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Akerna
0 Sell rating(s)

3 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Akerna had 3 more articles in the media than CompuMed. MarketBeat recorded 3 mentions for Akerna and 0 mentions for CompuMed. Akerna's average media sentiment score of -0.11 beat CompuMed's score of -0.86 indicating that Akerna is being referred to more favorably in the news media.
Company Overall Sentiment
CompuMed Negative
Akerna Neutral
: CompuMed has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Akerna has a beta of 2.73, meaning that its stock price is 173% more volatile than the S&P 500.
: CompuMed has a net margin of 6.42% compared to Akerna's net margin of -292.22%. CompuMed's return on equity of 10.95% beat Akerna's return on equity.
Company Net Margins Return on Equity Return on Assets
CompuMed 6.42% 10.95% 7.76%
Akerna -292.22% -70.76% -34.23%
: Akerna received 26 more outperform votes than CompuMed when rated by MarketBeat users.
Company Underperform Outperform
CompuMed N/A N/A
Akerna Outperform Votes
26
59.09%
Underperform Votes
18
40.91%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CompuMed	$6.36 million	0.56	$1.07 million	$0.32	9.38
Akerna	$20.68 million	0.15	-$31.33 million	-$43.59	-0.02

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CompuMed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Akerna	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Overall Sentiment
CompuMed	Negative
Akerna	Neutral

Company	Net Margins	Return on Equity	Return on Assets
CompuMed	6.42%	10.95%	7.76%
Akerna	-292.22%	-70.76%	-34.23%

Company	Underperform	Outperform
CompuMed	N/A	N/A
Akerna	Outperform Votes 26 59.09%	Underperform Votes 18 40.91%

Summary

CompuMed beats Akerna on 7 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPD vs. The Competition

Export to Excel

Metric	CompuMed	Data processing & preparation Industry	Medical Sector	OTCMKTS Exchange
Market Cap	$3.56M	$2.54B	$4.26B	$7.05B
Dividend Yield	N/A	1.85%	5.98%	18.10%
P/E Ratio	9.38	10.45	152.03	8.96
Price / Sales	0.56	6.31	3,583.00	289.32
Price / Cash	3.06	42.75	26.47	19.41
Price / Book	1.46	3.11	4.42	7.38
Net Income	$1.07M	-$38.34M	$115.31M	$727.60M
7 Day Performance	N/A	-0.90%	-2.76%	-0.71%
1 Month Performance	-14.04%	-11.45%	-6.79%	-2.15%
1 Year Performance	1,091.90%	-28.45%	-15.12%	-8.53%

CompuMed Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KERN Akerna	1.742 of 5 stars	$0.83 flat	$1.75 +110.8%	-26.4%	$3.34M	$20.68M	-0.02	204
MGTI MGT Capital Investments	0 of 5 stars	$0.01 flat	N/A	-64.2%	$4.49M	$880,000.00	0.00	2
ACUR Acura Pharmaceuticals	0 of 5 stars	$0.05 flat	N/A	N/A	$3.30M	$3.57M	0.00	12
MEDS TRxADE HEALTH	1.6875 of 5 stars	$0.36 flat	$7.00 +1,844.4%	-82.8%	$3.36M	$9.89M	-0.90	47	Upcoming Earnings
SLHG Skylight Health Group	0 of 5 stars	$0.09 flat	$3.00 +3,429.4%	-92.8%	$3.36M	$41.90M	0.00	80
HOTH Hoth Therapeutics	0 of 5 stars	$2.34 -5.6%	$66.50 +2,741.9%	-87.1%	$3.37M	N/A	-0.22	4	News Coverage
REMI Remedent	0 of 5 stars	$0.17 flat	N/A	N/A	$3.40M	$1.06M	0.00	2
GENN Genesis Healthcare	0 of 5 stars	$0.02 +100.0%	N/A	-93.8%	$3.41M	$3.91B	0.00	44,000	High Trading Volume
BXRX Baudax Bio	1.2249 of 5 stars	$1.33 -4.3%	$1.00 -24.8%	+72.3%	$3.44M	$1.27M	0.00	80	Positive News
PTPI Petros Pharmaceuticals	0 of 5 stars	$1.48 -3.3%	N/A	+30.8%	$3.06M	$7.81M	-0.10	27	Positive News Gap Down

This page (OTCMKTS:CMPD) was last updated on 3/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CompuMed - CMPD Competitors

CMPD vs. KERN, MGTI, ACUR, MEDS, SLHG, HOTH, REMI, GENN, BXRX, and PTPI

CompuMed vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPD vs. The Competition

CompuMed Competitors List

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info